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Articular cartilage damaged through trauma or disease has a limited ability to repair.
Untreated, focal lesions progress to generalized changes including osteoarthritis.
Musculoskeletal disorders including osteoarthritis are the most significant contributor
to disability globally. There is increasing interest in the use of mesenchymal stem cells
(MSCs) for the treatment of focal chondral lesions. There is some evidence to suggest
that the tissue type from which MSCs are harvested play a role in determining their ability
to regenerate cartilage in vitro and in vivo. In humans, MSCs derived from synovial tissue
may have superior chondrogenic potential. We carried out a systematic literature review
on the effectiveness of synovium-derived MSCs (sMSCs) in cartilage regeneration in
in vivo studies in accordance with Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) protocol. Twenty studies were included in our review;
four examined the use of human sMSCs and 16 were conducted using sMSCs
harvested from animals. Most studies reported successful cartilage repair with sMSC
transplantation despite the variability of animals, cell harvesting techniques, methods
of delivery, and outcome measures. We conclude that sMSC transplantation holds
promise as a treatment option for focal cartilage defects. We believe that defining the
cell population being used, establishing standardized methods for MSC delivery, and the
use of objective outcome measures should enable future high quality studies such as
randomized controlled clinical trials to provide the evidence needed to manage chondral
lesions optimally.
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INTRODUCTION
Damage to articular cartilage can occur as a consequence of trauma or disease (Thomas
et al., 2017). Cartilage is a relatively avascular structure, and has a limited ability to
repair (Convery et al., 1972). In an attempt to do so, inflammation ensues within the
joint with long term sequelae including osteoarthritis (Soren et al., 1976; Lohmander
and Roos, 2007). Musculoskeletal disorders including osteoarthritis are the most significant
contributor to disability globally (GBD 2015 Disease and Injury Incidence and Prevalence
Collaborators, 2016), and arthritis alone affects over 8 million people in the UK (National
Collaborating Centre for Chronic Conditions (UK), 2008). Osteoarthritis adversely affects
joint function and causes long term pain (Jordan et al., 2009). Management options
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for focal chondral lesions and its associated consequence such as
osteoarthritis are focused on symptom control or establishment
of a non-progressive state (Felson et al., 1995). Options such as
autologous chondrocyte implantation (ACI) have been explored
for focal chondral lesions, but they come with a variable success
rate and are associated with complications such as donor-site
morbidity (McCarthy et al., 2016). Other treatment options such
as acellular biomaterial implantation are resource intensive and
are associated with a high failure rate (Buma et al., 2003). The
end-stage treatment of osteoarthritis is a joint replacement but
this is costly and can have a poor outcome (Lenza et al., 2013).
This incurs a significant financial burden that is growing due to
an aging population and greater patient expectations.
One way to address the challenge of managing chondral
lesions may be through cell-based regenerative therapies.
Mesenchymal stem cell (MSC) transplantation is gaining
attention as a potential treatment option that reverses chondral
lesions (Trounson and McDonald, 2015). MSCs are multipotent
stem cells present in various sites of the body including the bone
marrow, dental pulp, adipose tissue, synovium, and umbilical
cord (Wexler et al., 2003; Lee et al., 2004; Ghorbani et al.,
2014; Hatakeyama et al., 2017). As MSCs can be harvested from
various tissues, many studies are now focused on ascertaining
the optimal cell source that provides the greatest number of
cells with the greatest chondrogenic potential (Ronzière et al.,
2010; Davies et al., 2017). There is some evidence to suggest
that the tissue type and anatomical site from which MSCs are
harvested play a role in determining their ability to regenerate
cartilage (Pizzute et al., 2015; Hatakeyama et al., 2017). There is
evidence to suggest that synovium-derived MSCs (sMSCs) may
have superior chondrogenicity in humans (Ogata et al., 2015),
and they may prove to be the optimal source cell as they are
native to the joints they are targeting. There are no cell surface
markers unique to sMSCs, and characterization is based on
generic epitopes of MSCs such as CD34, CD35, CD73, CD90, and
CD105 (Hermida-Gómez et al., 2011). The in vitro chondrogenic
differentiation of MSCs depends on exposure to appropriate
culture medium including TGF-β3 and glucocorticoids (Derfoul
et al., 2006; Bian et al., 2011). Type II collagen (COLII), aggrecan
(ACAN), and Sox9 gene expression allows for quantification of
chondrogenicity in MSCs in vitro (Akiyama et al., 2002; Mwale
et al., 2006; Tiruvannamalai Annamalai et al., 2016). Recent
studies have demonstrated that sMSCs exhibit greater expression
of some of these markers when compared to other MSCs e.g.,
bone marrow-derived MSCs (Ogata et al., 2015). MSCs may be
transplanted autologously, allogenically, or xenogenically.
It is suggested that MSCs mediate their chondrogenic
effects through direct or indirect mechanisms. Articular MSCs
within physiological joints demonstrate some ability to exert an
endogenous response to cartilage injury (Baboolal et al., 2016).
It has been shown through imaging studies that transplanted
MSCs are able to migrate to injured joints (Wood et al., 2012;
Maerz et al., 2017). However, resident cells are low in numbers
and typically go on to exhibit exhaustion followed by senescence
when full-thickness chondral lesions are incompletely repaired
(Fellows et al., 2017). Furthermore, MSC populations can
diminish as a function of age and disease (Asumda and Chase,
2011; Alt et al., 2012). Therefore, it may be beneficial to introduce
exogenous MSCs that can directly repair cartilage by producing
hyaline cartilage (Zhang et al., 2017) or by acting as a stimulus
for chondrogenic cells in addition to native MSCs. MSCs are able
to induce differentiation of chondroprogenitors to chondrocytes
through secretion of growth factors such as Transforming
Growth Factor β (TGF-β) and Fibroblast Growth Factor (FGF)
(Ng et al., 2008; Schinköthe et al., 2008) MSCs also secrete
prostaglandins (PGE) which subsequently increase Interleukin-
10 (IL-10) and decrease IL-12 secretion by dendritic cells (Beyth
et al., 2005; Saldaña et al., 2019). This has been shown to promote
a T-cell class switch from a pro-inflammatory Th1 to an anti-
inflammatory Th2 subtype (Beyth et al., 2005). This could be
a mechanism through which MSCs prevent inflammatory joint
disease progression. MSCs have also demonstrated the ability
to transduce signals via extracellular vesicles (EV) (Baglio et al.,
2015). EV released by MSCs have been shown to promote type
II collagen deposition in chondral lesions (Wang et al., 2017).
EVs that contain miR-140-5p are able to stimulate chondrocyte
proliferation and migration to sites of chondral lesion (Tao
et al., 2017). This trophic effect may be a mechanism through
which MSCs are translocated to sites of injury. Furthermore,
it has been shown that bone marrow-derived human MSCs
secrete hyaluronan-coated EVs that contain mRNA for CD44
(Arasu et al., 2017).
The transplantation of MSCs is now being tested in over
300 registered clinical trials (Trounson and McDonald, 2015).
In this PRISMA systematic review, we examine the potential for
sMSCs to regenerate cartilage by analyzing in vivo studies in
the literature.
MATERIALS AND METHODS
A systematic review of the literature was performed in
accordance with Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al.,
2015). A literature search from conception to January 2019 was
performed using PubMed, EmBase, Scopus, and Medline. The
following search terms were used: (((((synovial) OR synovium))
AND (((mesenchymal stem cell) OR MSC) OR stem cell)) AND
(((((cartilage) OR tendon) OR chondral) AN D (((repair) OR
regenerate) OR regeneration). Inclusion and exclusion criteria
were applied to the results of the search as follows:
Inclusion Criteria:
1. All articles in the English language with full text available.
2. Articles examining sMSCs using in vivo experiments.
3. Articles examining animal and human subjects.
4. Articles with subjects regardless of age, gender, race and pre-
treatment health.
5. Articles which examined autologous, allogenic and xenogenic
transplantation methods.
Exclusion Criteria:
1. Articles which were not translated into English language and
did not have full-text available.
2. Articles that conducted in vitro experiments exclusively.
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FIGURE 1 | Flow diagram illustrating search process.
3. Articles that investigated the repair of meniscal lesions
were excluded.
KT, BZ, and KR applied the search with above criteria
independently. A risk of bias analysis was carried out using
Cochrane’s tool; Risk of Bias 2.0 (RoB 2). This was performed
by BZ and KR independently. Each study was allocated a low,
intermediate or high risk of bias in accordance with the RoB
2.0 guidance in the five categories as shown in Figure 1. Various
signaling questions (Sterne et al., 2019) (Supplementary Table 1)
were answered in each category, the outcomes of the signaling
questions were averaged to produce an overall risk in each
of the five categories. An overall risk of bias was then
determined for each study by the cumulative result of these
five categories. A study was judged to be at high risk of
bias if it was at high risk for at least one category, or had
some concerns for multiple categories. A study was judged to
be of some concern if there were some concerns in at least
one category, but not to be at high risk in any category. A
study was judged to be at low risk of bias if at low risk of
bias for all five categories. The summary of the results as a
percentage of all the studies is represented in Figure 3. The
final articles were reviewed in full text for qualitative synthesis
by KT.
RESULTS
Three-hundred and fifty-four articles were found from PubMed.
An additional 35 articles were retrieved from three other sources.
No duplicates were identified. A total of 389 articles were
retrieved, the title and abstract of each article was screened for
appropriateness. Three-hundred and twenty six articles were
removed by application of the exclusion criteria.
Sixty-three full-text articles were reviewed. A total of 20
studies were obtained as shown in Figure 2. A total of 20 studies
were included in qualitative synthesis in this. Four out of 20
studies investigated human sMSCs and the remaining studies
assessed animal sMSCs.
The outcome of risk of bias analysis is summarized in
Figure 3. Twenty percentage of the studies in our review were
deemed to have an overall low risk of bias. Forty percentage of
the studies were thought to demonstrate high risk of bias and the
remainder were thought to demonstrate moderate risk of bias.
Studies of Human sMSCs
Table 1 includes details of the four in vivo studies that utilized
human sMSCs; two were case-control studies and two were
case series.
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FIGURE 2 | Summary of overall bias.
FIGURE 3 | Risk of bias in individual studies.
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TABLE 1 | Studies of human synovium derived MSC in the repair of cartilage in vivo.
References Study
design
Cell
source
Subject Number of
subjects
Number of
controls
Method of extraction Cell treatment Method of delivery Outcome
Li et al. (2018) Case
control
Human Murine 10 10 Arthroscopic flushing fluid
from knee joint
Flushing fluid cells were plated on
culture medium. Colony forming
assays, flow cytometry, and
proliferation assays were used to
validate MSCs. MSCs were
induced in chondrogenic medium
and subsequently fixed and
stained with Safranin O
Xenogenic injection of
MSC encapsulated in
polyPEGDA/HA hydrogel
into full thickness cartilage
defects in trochlear groove
Reduction in defect area compared
to control at 4 and 8 weeks
Shimomura et al.
(2018)
Case
series
Human Human
with knee
OA
5 N/A Arthroscopic biopsy Cultured cells were characterized
by flow cytometry for MSC
markers. They were not induced
into chondrogenic differentiation
Autologous implantation
of cultured
tissue-engineered
construct (TEC) into
chondral defects without
fixation
Improvement in PROMs for pain,
ADL, QoL, at 48 months. Secure
defect filling confirmed by second
look arthroscopy, improved MRI
score
Sekiya et al.
(2015)
Case
series
Human Human 10 N/A Arthroscopic biopsy of
subsynovial tissue on the
femur at the suprapatellar
pouch
Synovial MSCs were cultured with
Invitrogen containing antibiotics.
No in vitro assays were carried
out to assess chondrogenic
differentiation
Autologous injection of
cultured cells into femoral
condyle defect
Improved qualitative appearance in
cartilage defect filling in four out of
10 patients, improved MRI score
and increased Lysholm score at an
average 52 month follow up
Koizumi et al.
(2016)
Case
control
Human Murine 36 knees in
18 rats
4 knees in 2
rats
Arthroscopic biopsy of
synovium from knee joint
of patients with
rheumatoid arthritis or
with osteoarthritis or
without either
Synovial MSCs were cultured in
chondrogenic medium and
evaluated. Total RNA from
synovial MSC pellets were
analyzed using Real Time PCR.
qRT-PCR was also used to
assess gene expression. GAG
expression was quantified using a
protein assay.
Xenogenic transplantation
of MSC on a tissue
engineered scaffold
Osteochondral repair using MSC
derived from all patients were
superior to control. There was no
difference between cells from RA,
OA, or normal patients
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All human studies used an arthroscopic approach to the
knee in order to harvest sMSCs. Li et al. (2018) isolated sMSCs
from arthroscopic flushing fluid. The three other studies utilized
samples of synovial tissue from arthroscopic biopsies of the knee
joint. Two studies examined the effects of autologous sMSC
implantation following ex vivo expansion. The other two studies
carried out xenogenic transplantation and examined the effect of
human sMSC on murine models. The method of sMSC delivery
varied between the studies. All studies found that sMSCs, when
implanted into a chondral lesion, was superior in repairing
the lesion as compared with the various different controls or
untreated groups.
In the study by Li et al. (2018), human sMSCs from
arthroscopic flushing fluid were expanded ex vivo before
undergoing flow cytometry to analyze cell surface marker
expression (Li et al., 2018). Subsequently, one third of the cells
were subject to chondrogenic differentiation. Strong expression
of proteoglycans along with positive Safranin O immunostaining
was observed at 2 weeks following induction. The cells were
then encapsulated in hydrogel to form a composite method
of delivering sMSCs. The composite was subsequently injected
into full thickness chondral lesions in the trochlear groove of
the rat femur in 10 mice. Ten other mice were treated with
hydrogel alone without the sMSCs and another 10 served as a
control. The lesions were reassessed at 4 and 8 weeks following
treatment. Macroscopically, the group treated with hydrogel
and sMSC demonstrated a greater degree of defect filling. An
objective quantification of the macroscopic appearance as per the
International Cartilage Repair Society (ICRS) criteria confirmed
this. On histological analysis, the sMSC-treated group filled the
lesion with tissue that positively stained for Safranin O. Notably,
the lesions were partly filled with hydrogel treatment alone, albeit
this was reveal to be predominantly due to fibrous tissue forming
in the absence of cartilage. No overt complications were observed
in the murine subjects.
Koizumi et al. (2016) sought to assess whether source cells
from patients with rheumatoid arthritis (RA) or osteoarthritis
(OA) would differ in therapeutic potential. The disease
cohort comprised of patients who had undergone total knee
arthroplasty, arthroplasty of the forefoot and synovectomy
of the hand as a result of RA or OA. The sMSCs were
xenogenically implanted on a tissue engineered scaffold into
rat femoral trochlear groove osteochondral lesions. The in
vitro experiments showed no significant difference between
the groups in chondrogenic potential and cytokine expression.
Treated lesions showed higher histological scores compared with
untreated groups and there were no differences between the RA
and OA groups.
Shimomura et al. (2018) performed human autologous sMSC
transplantation in five patients with 1.5–3.0 cm2 symptomatic
chondral knee lesions. Synovial tissue was obtained through
biopsy using an arthroscopic approach and sMSCs were
subsequently cultured and characterized in vitro prior to
transplantation. Immunohistology analysis was carried out and
the cells were subsequently transferred onto a tissue engineered
construct before implantation. The constructs were implanted
into the defect site without fixation. The patients were follow-up
at intervals up to 48 weeks post-operatively. Magnetic resonance
imaging (MRI) was utilized to assess the chondral lesions. All
patients achieved full defect filling at 48 weeks post-intervention
as assessed by MRI. While no adverse effects were recorded in
the long term, all subjects had mild joint symptoms of pain that
resolved within 4 weeks. Some tissue edema was visualized on
MRI around the tissue construct at 6 weeks and at 24 weeks.
This was found to have resolved by 48 weeks for all cases. Tissue
integration and chondrogenesis were assessed histologically. The
regenerated tissue stained strongly for Safranin O. No adverse
clinical events were reported. The patients reported significant
clinical improvement at final 24 month follow-up.
Sekiya et al. (2015) explored the use of human sMSC
implantation in a symptomatic single femoral condyle chondral
lesion in 10 patients. Five patients underwent concomitant
procedures including ACL repair. Following isolation and
expansion of sMSCs in 10% autologous human serum for 14
days, a volume of 0.5mL was implanted into the chondral lesion
using a needle connected to a 10mL syringe. The qualitative
appearance was improved on second-look arthroscopy. There
was also an improvement inMRI score from 1.0 pre-intervention
to 5.0 post-intervention (p= 0.005). The histological appearance
of the lesions demonstrated the presence of hyaline cartilage and
fibrous cartilage. The patients were also assessed clinically and
the Lysholm score increased after treatment whereas the Tegner
Activity Level Scale did not decrease.
Studies of Animal sMSCs
Sixteen studies assessed the use of animal derived sMSCs, and
were conducted between 2007 and 2018 (Table 2).
Seven studies investigated sMSCs harvested from rabbit
synovium, two from murine synovium, one from equine
synovium, and six from porcine synovium. Three studies
extracted cells from synovial fluid and 13 studies obtained
cells via excision biopsy of the synovial membrane. All studies
implanted sMSCs into femoral chondral lesions. Out of the 16
studies, 13 performed allogenic transplantation, one performed
autologous and two performed xenogenic transplantation. A
total of 213 subjects were treated with sMSCs. Fourteen of 16
studies showed that sMSCs were superior to control in treating
full thickness chondral lesions. The method of delivering sMSCs
varied among the studies.
Schmal et al. (2018) compared cultured allogenic
chondrocytes with rabbit sMSCs in their ability to repair
osteochondral lesions in rabbit femur. Improved macroscopic
appearance was seen in the sMSC group as compared with
controls up to 24 weeks post-intervention. Pei et al. (2013)
employed a similar follow-up period extending to 6 months and
showed that in vitro engineered rabbit sMSC constructs were able
to regenerate rabbit chondral lesions (Pei et al., 2009). Through
histological assessment, they demonstrated smooth hyaline
cartilage in the treated group. Li et al. (2016) attempted to qualify
the cartilage quality of repaired osteochondral lesions in rabbit
knees treated with rabbit sMSC injection. Their experiment
showed no significant difference in macroscopic, Modified
O’Driscoll (MOD) and Magnetic resonance Observation of
CArtilage Repair Tissue (MOCART) scores. However, using
Deuterium Weighted Imaging (DWI) and T2 imaging settings
on MRI, the group was able to reveal greater tissue quality
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TABLE 2 | Studies of MSCs derived from animal synovium in the repair of cartilage in vivo.
References Cell
source
Subject Number of
subjects
Number of
controls
Method of extraction Cell expansion Method of delivery Outcome
Schmal et al.
(2018)
Rabbit Rabbit 6 6 Excisional biopsy of
synovium from knee of
rabbit
MSCs were cultured in
chondrogenic media for 21 days.
Chondrogenic differentiation was
evaluated through RNA analysis
using qPCR
Allogenic transplantation of
sMSC into full-thickness
cartilage lesions in central
medial femoral condyle
Improved ICRS in sMSC group at up
to 24 weeks, improved macroscopic
appearance
Pei et al. (2009) Rabbit Rabbit 12 12 Synovial tissue from knee
joint O
Passage 3 synovial MSCs were
attached onto PGA mesh and
incubated in a bioreactor containing
growth factors for 4 weeks. The
samples were analyzed with
immunohistology and western blot
to confirm chondrogenic
differentiation
Allogenic implantation of
sMSCs on cell-engineered
tissue construct into full
thickness femoral condyle
cartilage defect
Improved qualitative appearance of
cartilage defect at 6 months
Lee et al. (2013) Rabbit Rabbit 27 27 Excisional biopsy of
infrapatellar fat pad
Synovial MSCs were suspended in
chondrogenic culture medium,
histological analysis was utilized to
determine GAG expression and
immunohistology was used to
determine Collagen II expression at
4 weeks after cultivation
Allogenic transplantation of
synovial membrane derived
MSCs supported by platelet
rich plasma (PRP) into
osteochondral defect in
trochlear groove of femur
Improved qualitative macroscopic
appearance and histological findings
Shimomura et al.
(2014)
Rabbit Rabbit 23 18 Excision of synovial
membrane from knee
joints of rabbits
Synovial MSCs were suspended in
growth medium containing DMEM
and FBS. Cells at passage 3–7
were utilized
Allogenic implantation of
combined implant made of
scaffold-free tissue
engineered construct from
MSCs and Hydroxyapatite
artificial bone into a
osteochondral defect of
femoral groove
Improved histological scores and
improved macroscopic appearance
at 1, 2, and 6 months
Li et al. (2016) Rabbit Rabbit 5 5 Excision of synovial tissue
from knee joint
Synovial MSCs were isolated and
incubated in culture flasks
containing chondrogenic medium.
The cells were not assessed for
chondrogenic differentiation
Allogenic injection of MSC
into full-thickness cartilage
defect in central portion of
femoral trochlea groove
No significant difference in MSC vs.
control group in macroscopic and
MRI scores. Improvement in tissue
quality was observed by MRI
Lee et al. (2012) Rabbit Rabbit 20 20 Synovial tissue from knee
joint
Second passage synovial MSCs
were trypsinized and suspended in
a composite gel containing
collagen, hyaluronic acid, and
fibrinogen. The cells were then
cultured on a plate with
chondrogenic medium. Proliferation
assay, RT-PCR, Real Time PCR,
and GAG staining were used to
assess chondrogenic differentiation
Allogenic injection of SDCS
in a composite gel into full
thickness defect in the
patellar groove of the distal
femur
Improved macroscopic scores for Gel
SDSC group vs. control, increased
immunostaining
(Continued)
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TABLE 2 | Continued
References Cell
source
Subject Number of
subjects
Number of
controls
Method of extraction Cell expansion Method of delivery Outcome
Jia et al. (2018) Rabbit Rabbit 6 6 Synovial fluid from knee
joint obtained through
arthrocentesis
Cells were isolated from pellets
which were formed by
centrifugation of synovial fluid. The
cells were culture expanded and
induced by chondrogenic
differentiation medium. Histological
staining and qRT-PCR were used to
quantify chondrogenic marker
expression e.g., Col2A1, Sox9, and
LPL
Allogenic intra-articular
injection into cartilage
defects of the patellar
groove of femur weekly for 4
weeks
Improved ICRS scores in
predifferentiated chondrogenic MSCs
treated compared to control groups,
a third undifferentiated MSC group
was also used and was found to be
superior to predifferentiated group in
ICRS macroscopic score at 12 weeks
Hori et al. (2011) Murine Murine 24 24 Excision of synovial
membrane at medial
femoral condyle
Harvested synovium MSCs were
expanded on plates with culture
medium. Passage 3 cells were
magnetically labeled.
Chondrogenesis in vitro was
assessed with histological staining
using Safranin-O
Allogenic transplantation of
feroxide labeled synovial
MSC into osteochondral
defect on articular cartilage
of patellar groove of distal
femur with a permanent
magnet placed
Increased thickness of regenerated
cartilage as compared with control,
stem cells with magnets performed
better than stem cells alone,
increased histological scores
Mak et al. (2016) Murine Murine 9 43 Biopsy of synovium of
knee joint
Synovial MSCs were seeded into
plates and chondrogenic medium
was added. qPCR was used to
quantify expression of
chondrogenic markers including
Sox9, Col2A1, and ACAN
Allogenic intra-articular
injection of MSCs into a full
thickness focal cartilage
defect in the femur
Increased cartilage repair in both
groups, improved MRI appearance,
and histological scores
Zayed et al.
(2018)
Equine Murine Not available Not available Culture of sMSC derived
from synovial fluid in
previous experiment
sMSCs were cultured in DMEM
media with TGF-β1 for 14 days.
Western blot analysis was used to
analyze chondrogenic differentiation
Xenogenic transplantation of
fluorescently labeled MSCs
encased in agarose scaffold
constructs into full thickness
cartilage defect in the
trochlear groove of rat femur
Improved Macroscopic appearance in
sMSC treated knees vs. control,
sMSC treated knees demonstrated
higher type II collagen expression.
Pei et al. (2010) Porcine Rabbit 12 12 Biopsy of intimal layer of
synovium from knees joint
Synovial MSCs were
culture-expanded in vitro and
passaged once prior to seeding
onto tissue engineered construct
composed of polyglycolic acid
(PGA). The construct was incubated
for 1 month in chondrogenic growth
media in a bioreactor
Xenogenic transplantation of
tissue engineered construct
into medial femoral condyle
of surgically induced
osteochondral defects
Improved defect filling in the treated
group at 3 weeks by macroscopic
appearance. At 6 months, worsened
macroscopic appearance in the
treated group as compared with the
control group. Improved histological
scoring in the control group
compared to the treated group
Ando et al.
(2007)
Porcine Porcine 6 3 Excision of synovial
membrane from knee joint
Synovial MSCs were expanded in
vitro and cultured in chondrogenic
medium containing recombinant
BMP2. Immunohistology and
RT-PCR were used to confirm
expression of chondrogenic
markers
Allogenic implantation of
tissue engineered construct
into chondral defects in
medial femoral condyle
Improved ICRS scores in TEC
implanted subjects compared to
control at 6 months
(Continued)
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TABLE 2 | Continued
References Cell
source
Subject Number of
subjects
Number of
controls
Method of extraction Cell expansion Method of delivery Outcome
Shimomura et al.
(2010)
Porcine Porcine 14 10 Biopsy of synovial
membranes of knee joint
Synovial MSCs were isolated from
membranes and plated in dishes
with chondrogenic medium. A pellet
culture system was used to assess
in vitro chondrogenesis. RT-PCR
was used to detect Collagen II
expression. GAG synthesis was
confirmed by Alcian blue staining
Allogenic implantation of
MSCs on tissue engineered
constructs into chondral
defects on the medial
condyle
Improved macroscopic and
histological scores in treated vs.
untreated groups (ICRS histological
score). No difference between
whether tissue was harvested from
mature or immature pigs at 6 months
post implantation
Chiang et al.
(2014)
Porcine Porcine 12 12 Aspiration of needle
flushing fluid from
synovium of knee joint
Synovial fluid was centrifuged into
pellets. The pelleted cells were
suspended in DMEM culture and
subsequently injected into PRP
composite hydrogels.
Immunohistology and Real Time
PCR were used to evaluate
chondrogenic gene expression
Autologous implantation of
MSC with
platelet-rich-plasma (PRP)
composite hydrogel
Improved macroscopic appearance
when treated with MSC in hydrogel
compared with controls (without
MSC—which demonstrated
degradation of the hydrogel complex)
at 4 and 8 weeks follow up, greater
amount of ECM deposition in treated
group
Pei et al. (2013) Porcine Porcine 20 6 Biopsy of synovial
membrane in knees of
pigs
Expanded synovial MSCs were
centrifuged into pellets. The pellets
were cultured in chondrogenic
medium and analyzed for
chondrogenic differentiation at 0, 7,
and 14 days following incubation.
RT-PCR and immunohistology were
used to examine chondrogenic
differentiation
Allogenic injection of
expanded cells into partial
thickness cartilage defects
in porcine medial femoral
condyle
Improved macroscopic appearance
with treated groups, greater
histological scores at 3 months
Nakamura et al.
(2012)
Porcine Porcine 7 7 Biopsy of suprapatellar
pouch synovium through
arthrotomy of knee joint
Synovial MSCs were plated and
culture expanded. The cells were
transformed into pellets by
centrifugation and cultured in
chondrogenic medium containing
DMEM, BMP7, TGF, etc. The
pellets were assessed histologically
with Safranin O staining
Allogenic transplantation of
MSC into full thickness
osteochondral defects in
medial femoral condyle
Improved macroscopic appearance
of defect—thicker white membrane at
2 months on arthroscopic Inspection.
Significantly improved ICRS score in
treated groups
F
ro
n
tie
rs
in
B
io
e
n
g
in
e
e
rin
g
a
n
d
B
io
te
c
h
n
o
lo
g
y
|
w
w
w
.fro
n
tie
rsin
.o
rg
9
N
o
ve
m
b
e
r
2
0
1
9
|V
o
lu
m
e
7
|
A
rtic
le
3
1
4
To et al. Synovium-Derived Mesenchymal Stem Cell Transplantation
in the treated group. Jia et al. (2018) investigated the effects
of intra-articular injection of rabbit sMSCs in rabbit patellar
groove osteochondral lesions by comparing predifferentiated
and undifferentiated rabbit synovial fluid derived sMSCs.
Predifferentiated sMSCs performed better than control groups
in cartilage repair as measured by ICRS and macroscopic
appearance. However, undifferentiated sMSCs were found to be
superior to pre-differentiated sMSCs.
A number of studies on the rabbit model sought to investigate
the effects of gels and scaffold. Lee et al. (2013) investigated
platelet-rich plasma gel (PRP) for the delivery of sMSCs. Rabbit
sMSCs were suspended on blood supernatant containing PRP
and injected allogenically into full thickness chondral lesions.
The PRP gel was observed to bind to chondral lesions and bone
within 10min following injection. At 24 weeks, the treated group
demonstrated significantly improved macroscopic scores as
compared with control. However, the microscopic appearances
of the lesions in the treated groups were not significantly different
to the untreated groups until 12 weeks post-intervention. The
effects of combining different constructs were explored in a study
by Shimomura et al. (2014). They merged tissue engineered
construct made from sMSCs with a hydroxyapatite (HA) bone.
The combined material was implanted into full thickness lesions
in rabbits and was compared to a control group in which only
HA was utilized. It was found that the sMSC construct integrated
quickly with the HA artificial bone. The sMSC groups achieved
rapid cartilage repair and demonstrated improved osteochondral
appearances compared with the control group which showed
changes consistent with early osteoarthritis-like features at 6
month follow-up. Lee et al. (2012) investigated the effects
of intra-articular injection of rabbit sMSCs in rabbit patellar
groove osteochondral lesions. The sMSCs were suspended in
a collagen/hyaluronic acid/fibrinogen (COL/HA/FG) gel. This
was compared to controls that received COL/HA/FG alone. The
treated groups demonstrated greater Safranin-O and type II
collagen staining.
Hori et al. (2011) labeled murine sMSCs with ferumoxides
and treated chondral lesions by direct implantation (Hori et al.,
2011). Permanent magnets were simultaneously implanted into
the bottom of murine lesions. Chondral lesions treated with
both labeled sMSCs and implanted magnets outperformed non-
labeled sMSCs in histological scores. Cartilage thickness was
also found to be greater in the labeled group. Mak et al. (2016)
evaluated subsets of murine sMSCs and assessed their ability
to regenerate cartilage in mice. Sca-1 positive Murphy’s Roth
Large mice (MRL/MpJ) derived “healer” sMSC subsets did not
perform better than non-healing C57BL6 sMSC subsets. Both
groups demonstrated similar cartilage repair outcomes at 4 weeks
post-treatment. The MRL/MpJ group also persisted in the defect
for longer than the C57BL6 subset.
Zayed et al. (2018) undertook a study to compare the
ability of equine sMSCs to regenerate cartilage defects in
murine models with bone marrow derived MSCs. The xenogenic
transplantation study showed increased amount of type II
collagen in sMSC-repaired lesions as compared with bone
marrow derived MSC-treated lesions. Pei’s group undertook a
xenogenic transplantation study of sMSCs on a tissue engineered
construct (Pei et al., 2010). sMSCs were incubated with a PGA
scaffold in a bioreactor with chondrogenic growth factors for a
duration of 4 weeks. Following that, the scaffolds were implanted
into rabbit knee osteochondral defects and observed for 6
months. Positive results in macroscopic appearance were seen in
favor of the treated group at 3 weeks. At 6 months, quantitative
histological measures reveal increased tissue loss in the treated
groups as compared with control groups. The control groups
displayed an improved macroscopic appearance compared to the
treated group.
Five separate studies examined the effects of porcine sMSCs
on porcine chondral lesions. Ando et al. (2007) implanted sMSCs
via a tissue engineered construct into medial condyle chondral
lesion and found an improved ICRS score in implanted subjects
at up to 6 months. Shimomura et al. (2010) examined the
chondrogenicity of sMSCs as a function of age. They found
no significant difference between mature and immature porcine
sMSCs in treating osteochondral lesions in the knee. Chiang
et al. (2014) explored the utility of a PRP composite gel in
delivering sMSCs and similarly to Lee et al. (2012) found this to
be an effective method on long term follow-up. Pei et al. (2013)
allogenically transplanted ex vivo expanded sMSCs grown on a
decolorized matrix into partial thickness lesions and observed an
improvement at 3 months. Nakamura et al. (2012) looked at the
effects of porcine sMSCs in treated full thickness chondral lesions
when transferred allogenically via a minimally invasive approach.
They found a significantly improved ICRS score andmacroscopic
appearance in the treated group (Nakamura et al., 2012).
DISCUSSION
The studies included in our review demonstrated overall positive
outcomes with sMSC transplantation, and generally without
complications. All but one study demonstrated significant
improvement in cartilage repair as stipulated by various outcome
measures when compared with controls that did not receive
sMSCs. Two studies compared MSCs from synovium with MSCs
from another source. Zayed’s group extracted MSCs from equine
joint synovium and bone marrow (Zayed et al., 2018), and
performed a xenogenic transplantation study to compare the
two sources in their ability to regenerate murine cartilage. Their
results suggest that sMSCs have superior chondrogenic potential
both in vitro and in vivo. Nakamura et al. (2012) compared
sMSCs to bone marrow, muscle, periosteum and adipose derived
MSCs, and found sMSCs to have greater chondrogenic potential
in vitro (Nakamura et al., 2012).
All included studies were case-control studies on the effect
of sMSC transplantation in vivo in humans or animal models.
The studies included in this review explored a variety of different
animal models. While the variation makes it difficult to draw
comparisons, it does suggest sMSCs to be a robust cell source
for cartilage repair. Although most studies suggest that cells
isolated from different mammalian animals appear not to vary
significantly in in vitro differentiation potential, Scuteri et al.
(2014) suggest that cell harvest from murine may derive sMSCs
with significantly different chondrogenicity when compared to
human cell sources (Scuteri et al., 2014). It is difficult to
envision future cell based therapies for human chondral lesions
using xenogenic transplantation due to potential immunological
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implications. Pei et al.’s study of xenogenic sMSC transplantation
reported poorer cartilage repair in the treated group at long term
review, they suggested that this could be attributed to delayed
immune rejection of the transplanted sMSCs (Pei et al., 2010).
Although the studies in this review did not specifically explore
these particular effects, there is some evidence to suggest that
xenogenic MSC transplantation may dampen rather than trigger
host T-cell responses (Ezzelarab et al., 2011).
In the studies included in our review, sMSCs were isolated
either by excisional biopsy of synovial membrane or extraction
of intra-articular fluid. Fülber et al. in their in vitro study
suggested that MSCs derived from joint cavity fluid have greater
in vitro chondrogenic potential in comparison to MSCs derived
from the synovial membrane itself (Fülber et al., 2016). While
there was relative consistency in method of harvest, the joint
phenotypes varied significantly. This is however probably not
important in humans as Koizumi et al. (2016) demonstrated that
the joint phenotype from which MSCs are isolated had little
effect on MSC chondrogenic potential (Koizumi et al., 2016). It
is difficult to obtain significant numbers of sMSCs from direct
harvest, and most studies culture-expanded sMSCs ex-vivo prior
to transplantation. Some studies suggested that resident MSC
number and chondrogenicity vary as a function of age. This may
introduce difficulty in conducting reliable pooled analysis of the
results. Furthermore, while the studies in this review harvested
cells from joints there may still be variation in chondrogenicity.
The method of sMSC delivery varied significantly between the
studies reviewed. This ranged from direct intra-articular
injection, transfer on cellularized matrices, transfer on
engineered acellular biomaterial scaffolds and homing by
magnetism through injection of ferumoxide into MSCs (Hori
et al., 2011; Jia et al., 2018; Zayed et al., 2018). Successful
cartilage repair following direct injection of sMSCs may reflect
the ability of synovial MSCs to home to chondral lesions.
Transfer on a scaffold may control for this effect and allow more
direct assessment of chondrogenic potential as the sMSCs are
artificially directed to the site of the lesion. Manipulation of
sMSCs by other methods, such as incorporation of ferrous metals
may alter the biology of sMSCs. While this creates difficulty in
direct comparison when interpreting results, it may allow for
a meaningful subgroup analysis if aggregate sample sizes were
adequately large. The results suggest that sMSCs are ubiquitously
efficacious regardless of method of delivery and can be utilized
in various forms depending on the lesion in question. These
findings may also apply to MSCs from other tissue sources.
The exact mechanism for the suggested superior
chondrogenicity of sMSCs compared to other cell sources have
not been elucidated. Ogata suggests that it could be due to the
increased prevalence of certain MSC subpopulations that carry
a greater propensity to undergo chondrogenic differentiation
(Ogata et al., 2015). It may be that sMSCs exhibit a greater ability
to proliferate in vitro, and thus is less labor intensive to expand
prior to transplantation. Particular studies have examined the
proliferation rate of sMSCs in comparison to adipose-derived
MSCs and found sMSCs to be superior (Mochizuki et al.,
2006). In the same study, sMSCs were shown to have greater
chondrogenic potential than adipose-derived MSCs.
As cell-based therapies for chondral defects are gaining more
attention, MSCs are becoming more extensively investigated.
Recently, studies have attempted to clarify the effects of
MSC-derived exosomes in cartilage repair in vitro (Vonk et al.,
2018) and in vivo (Tao et al., 2017;Wang et al., 2017). The authors
from these studies attribute the positive effects of exosomes in
cartilage repair to their modulatory effects on gene expression. In
vivo studies exploring different delivery methods of these MSC
secretomesmay help identify themost effective way of translating
these findings to clinical application.
One of the main limitations of this review was the
heterogeneity between the studies in the methods used to
assess outcomes. The objective quantitative measures of cartilage
repair included macroscopic, histological, biomechanical
and biochemical evaluations. The most commonly employed
macroscopic scoring was the ICRS score, whereas most studies
applied a unique subject score. The MOD score was the most
used histological measure of cartilage repair, and was used in
one-third of the studies. Macroscopic scoring systems based
on defect appearance are subject to observer bias and are
difficult to address. The use of a single operator could result
in overestimation of therapeutic benefits, whereas multiple-
operators could introduce inter-user variability (Moojen
et al., 2002). In the future, the bias may be eliminated with
computer algorithms delivering a reproducible assessment
(Moussavi-Harami et al., 2009). Two human studies used Patient
Reported Outcome Measures (PROMs) and demonstrated an
improvement following sMSC treatment (Sekiya et al., 2015;
Shimomura et al., 2018). While in human studies, this may be the
most effective way of assessing the outcomes of MSC treatment,
animals studies will need to rely on objective mechanical
assessments such as gait analysis and weight-bearing distribution.
The majority of the studies in this review were at intermediate
to high risk of bias as determined by the ROB-2 Cochrane risk
assessment tool. For the purposes of drawing conclusions from a
systematic review, an overall high risk of bias may invite caution
in interpreting pooled outcomes. Whereas, an overall low risk of
bias may suggest greater reliability of the conclusions drawn from
a systematic review. Dissection of individual bias levels assigned
to studies may help to elucidate elements lacking between studies
and guide future study design. The main contributor to increased
risk of bias was poor randomization processes in determining
the experimental and control cohorts. Furthermore, there was
significant subjectivity in certain outcome measures employed
by most of the studies e.g., in histological scoring and scoring
macroscopic cartilage appearance. We believe that the studies on
MSCs used for cartilage repair could be improved in a number
of ways including the characterization of sMSCs by identification
of surface epitopes, standardization of MSC delivery methods by
determining the optimal volume or cell number for a given defect
size, and the use of objective quantitative measures.
CONCLUSION
Regenerative approaches may be the most promising option
for treating chondral lesions and preventing osteoarthritis.
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Cell-based therapies such as MSC transplantation are proving
to be effective in in vitro and in vivo studies. The search
for an optimal cell source will help guide translation to
clinical application in humans. In this review we have
shown that MSCs derived from synovial tissue have good
chondrogenic potential. Defining the cell population being
used, establishing standardized methods for MSC delivery, and
the use of objective outcome measures should enable future
high quality studies such as randomized controlled clinical
trials to provide the evidence needed to manage chondral
lesions optimally.
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